Principal Investigator
Michele Stanchina
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240911
Clinical Trial Summary
NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial with Either Rituximab or Mosunetuzumab
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Lymphoma
Contact Information
Phone Number
+1 (305) 2437261